ID
24787
Descrição
Study ID: 101468/166 Clinical Study ID: SKF-101468/166 Study Title: A Phase II, randomised, double-blind, active-controlled, dose-escalation study to determine the maximum well-tolerated starting dose of a new formulation of ropinirole in Parkinson's Disease patients not receiving other dopaminergic therapies Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 2 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: requip Study Indication: Parkinson Disease
Palavras-chave
Versões (4)
- 17/08/2017 17/08/2017 -
- 23/08/2017 23/08/2017 -
- 04/09/2017 04/09/2017 -
- 04/09/2017 04/09/2017 -
Titular dos direitos
GlaxoSmithKline
Transferido a
17 de agosto de 2017
DOI
Para um pedido faça login.
Licença
Creative Commons BY-NC 3.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
laboratory evaluation urinalysis determination of the maximum well-tolerated starting dose of ropinirole in Parkinson's Disease 101468/166
laboratory evaluation urinalysis determination of the maximum well-tolerated starting dose of ropinirole in Parkinson's Disease 101468/166
Similar models
laboratory evaluation urinalysis determination of the maximum well-tolerated starting dose of ropinirole in Parkinson's Disease 101468/166
C0011008 (UMLS CUI [1,2])